`
`From:
`Sent:
`To:
`
`Cc:
`
`Christopher Evans <cevans@ShoreChan.com >
`Wednesday, October 11, 2017 7:39 AM
`Torczon, Richard
`
`Parmelee, Steve; Alfonso 6 Chan; IPR01227; kane@fr.com; whelan@fr.com;
`
`morrison@fr.com,' Rosato, Michael; Mills, Jad; Devine, Wendy; Carsten, Douglas;
`
`Phillips, Anna; mdzwonczyk@sughrue.com; akokabi@sughrue.com;
`tribar@sughrue.com; sblackston@sughrue.com; gspeier@carlsoncaspers.com;
`
`mschuman@carlsoncaspers.com; IPRCyclosporine@carlsoncaspers.com; White,
`Brandon (Perkins Coie); Restasis@perkinscoiecom; Michael Shore
`
`Subject:
`
`RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132 (the IPRs)
`
`Richard,
`
`After you file your brief we can confer about what, if anything, needs to remain under seal.
`
`Best,
`
`Chris Evans
`
`SCI) I SHORE CHAN
`
`DEPUMPO up
`
`Christopher L. Evans
`Shore Chan DePumpo LLP
`901 Main Street, Suite 3300
`
`Dallas, Texas 75202
`
`214-593-91 18 (Direct)
`214-593-9110 (Firm)
`214-593-9111 (Fax)
`
`NOTICE OF CONFIDENTIALITY:
`The information contained in and transmitted with this e-mail may be subject to the Attorney-Client and Attorney Work Product privileges, and is
`Confidential. It is intended only for the individuals or entities designated as recipients above. You are hereby notified that any dissemination, distribution,
`copying, use or reliance upon the information contained in and transmitted with this e—mail by or to anyone other than the addressee designated above by the
`sender is unauthorized and strictly prohibited. Ifyou have received this e—mail in error, please notify the sender by reply immediately. Any e—mail erroneously
`transmitted to you should be immediately destroyed.
`
`From: Torczon, Richard [mailto:rtorczon@wsgr.com]
`
`Sent: Tuesday, October 10, 2017 5:08 PM
`To: Christopher Evans <cevans@ShoreChan.com>
`
`Cc: Parmelee, Steve <sparmelee@wsgr.com>; Alfonso G Chan <achan@ShoreChan.com>; |PR01227
`
`<lPR01227@ShoreChan.com>; kane@fr.com; whelan@fr.com,' morrison@fr.com; Rosato, Michael
`
`<mrosato@wsgr.com>; Mills, Jad <jmi|ls@wsgr.com>; Devine, Wendy <wdevine@wsgr.com>; Carsten, Douglas
`<dcarsten@wsgr.com>; Phillips, Anna <anphi|lips@wsgr.com>,' mdzwonczyk@sughrue.com; akokabi@sughrue.com;
`tribar@sughrue.com; sblackston@sughrue.com; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com;
`
`lPRCyclosporine@carlsoncaspers.com; White, Brandon (Perkins Coie) <BMWhite@perkinscoie.com>;
`
`Restasis@perkinscoie.com; Michael Shore <mshore@ShoreChan.com>
`
`Subject: RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132 (the IPRs)
`1
`MYLAN - EXHIBIT 1166
`  
`
`

 
`Mylan Pharmaceuticals Inc. et a1. V. Allergan, Inc.
`
`  
`
`IPR2016-01127, -01128, -01129, -01130, -01131, -01132
`
`!"# # "$ # "% # "& # '# # ' # '"
`
`

`

`) *
`
`+,-./0
`
`0 1
`
`20+34205670-8257-9-28035:0;:<35=>659-8257-3<0-596,?37-650-507+206,82,@00A-?-<3,<:/0B20+34205670-8257-9-280
`;:<35=>659-8257-3<0-596,?37-650-507+20<3.7=9-<2807,35.>,-C70DEF@0GGHIJ0.60:6K0>350384-.207+20L63,80B20+3420560
`6MN2>7-650760?3O-5P0-70CKM<->03.0B2<<@0
`
`0 A
`
`-5>20?K>+06907+20K582,<:-5P03P,22?257.0+3.03<,238:0M2250?3820CKM<->0D96,02F3?C<2/07+,6KP+0,292,25>2.0-507+20
`Q,-M2R.0?67-65J/0-70B6K<80M20+2<C9K<0-90:6K0>6K<80C,64-820K.0B-7+030+-P+<-P+728042,.-650690EF+-M-7.0STUV03580
`STUW0-58->37-5P0B+->+0?372,-3<0,2?3-5.0>659-8257-3<@00X6-5P0.60B-<<093>-<-73720M,-29-5P03580C6..-M<:0.C3,20K.0
`M67+07+205228076082>-820B+27+2,09K7K,20C3C2,.0?K.70M209-<280-50>659-825>2@0
`
`0 Y
`
`2P3,8./0
`Y->O0
`
`0 Z
`
`[\]^_`abcdefgahb_ijkld_mnkcoefpqhjkldrsafbh`akltqfnu__
`vwxy^_z{hd|k}~_€_qef‚hb~_(€ƒ_„t…(_
`†\^_‡cqakho_safbhˆ_zfbq‰fl~_Šcqakb|_
`‹Œ^_kbnhohh~_sehjhˆ_Žofldf__`aklˆ_‘Š€((ƒˆ_’klhrbtqfnˆ_“ahoklrbtqfnˆ_nfbbcdflrbtqfnˆ_Šfdkef~_‡cqakhoˆ_
`‡cood~_”k|ˆ_•hjclh~_–hl|}ˆ_`kbdehl~_•f{—okdˆ_acoocgd~_Žllkˆ_n|‰“flq‰}’rd{—ab{htqfnˆ_k’f’k‚crd{—ab{htqfnˆ_
`ebc‚kbrd{—ab{htqfnˆ_d‚okq’deflrd{—ab{htqfnˆ_—dghchbrqkbodflqkdghbdtqfnˆ_ndqa{nklrqkbodflqkdghbdtqfnˆ_
`‘Š`}qofdgfbclhrqkbodflqkdghbdtqfnˆ_–aceh~_˜bkl|fl_™hb’cld_`fchš_
`v›œwŒy^_Šip_‘Š(€„ž€(ƒ~_€(Ÿ~_€( ~_€¡€~_€¡~_kl|_€¡(_™eah_‘Šdš_
`
`) ¢
`
`£¤¥¦§¨©)
`
`) ª
`
`«)¨¬)­¬®)¯«°£«±«)®¥£²)¬§¨«§)­««¨²)®¬)¯«)²«¦°«¨³)´°«¦²«)°«®)µ«)¶­¬·)·¥¦®)¸¬¹§)º¬²£®£¬­)£²)²¬)·«)¤¦­)»¬£­®°¸)£­¼¬§µ)®¥«)
`½¬¦§¨³)
`
`) ½
`
`«²®©)
`
`) ¾
`
`¥§£²)¿±¦­²)
`
`) ) ) À
`
`)
`
`À Á
`
`ÂÃÄÅÆÇÈÂÉÃÀÊËÀÌÍÎÏÅÀ
`ÐÂÇÃÉÀÁÂÎÏÀÑÉÒÓÔÈÇÀÊÊÒÀ
`ÕÖ×ÀØÎÄÏÀÐÆÃÉÉÆÙÀÐÓÄÆÉÀÚÚÖÖÀ
`ÑÎÛÛÎÅÙÀÜÉÝÎÅÀÞßàÖàÀ
`à×áâßÕÚâÕ××ãÀäÑÄÃÉåÆæÀ
`à×áâßÕÚâÕ××ÖÀäçÄÃÔæÀ
`à×áâßÕÚâÕ×××ÀäçÎÝæÀ
`
`Àè
`
`éêëìíîéïîìéèïëðíèêëñòëêóôîî
`ÜÂÉÀÄÏõÇÃÔÎÆÄÇÏÀåÇÏÆÎÄÏÉöÀÄÏÀÎÏöÀÆÃÎÏÅÔÄÆÆÉöÀ÷ÄÆÂÀÆÂÄÅÀÉâÔÎÄÛÀÔÎøÀùÉÀÅÓùúÉåÆÀÆÇÀÆÂÉÀûÆÆÇÃÏÉøâÁÛÄÉÏÆÀÎÏöÀûÆÆÇÃÏÉøÀüÇÃýÀÀÒÃÇöÓåÆÀÈÃÄÍÄÛÉþÉÅÙÀÎÏöÀÄÅÀ
`ÁÇÏõÄöÉÏÆÄÎÛËÀÀÆÀÄÅÀÄÏÆÉÏöÉöÀÇÏÛøÀõÇÃÀÆÂÉÀÄÏöÄÍÄöÓÎÛÅÀÇÃÀÉÏÆÄÆÄÉÅÀöÉÅÄþÏÎÆÉöÀÎÅÀÃÉåÄÈÄÉÏÆÅÀÎùÇÍÉËÀÀ ÇÓÀÎÃÉÀÂÉÃÉùøÀÏÇÆÄõÄÉöÀÆÂÎÆÀÎÏøÀöÄÅÅÉÔÄÏÎÆÄÇÏÙÀöÄÅÆÃÄùÓÆÄÇÏÙÀ
`åÇÈøÄÏþÙÀÓÅÉÀÇÃÀÃÉÛÄÎÏåÉÀÓÈÇÏÀÆÂÉÀÄÏõÇÃÔÎÆÄÇÏÀåÇÏÆÎÄÏÉöÀÄÏÀÎÏöÀÆÃÎÏÅÔÄÆÆÉöÀ÷ÄÆÂÀÆÂÄÅÀÉâÔÎÄÛÀùøÀÇÃÀÆÇÀÎÏøÇÏÉÀÇÆÂÉÃÀÆÂÎÏÀÆÂÉÀÎööÃÉÅÅÉÉÀöÉÅÄþÏÎÆÉöÀÎùÇÍÉÀùøÀÆÂÉÀ
`ÅÉÏöÉÃÀÄÅÀÓÏÎÓÆÂÇÃÄÉöÀÎÏöÀÅÆÃÄåÆÛøÀÈÃÇÂÄùÄÆÉöËÀÀõÀøÇÓÀÂÎÍÉÀÃÉåÉÄÍÉöÀÆÂÄÅÀÉâÔÎÄÛÀÄÏÀÉÃÃÇÃÙÀÈÛÉÎÅÉÀÏÇÆÄõøÀÆÂÉÀÅÉÏöÉÃÀùøÀÃÉÈÛøÀÄÔÔÉöÄÎÆÉÛøËÀÀûÏøÀÉâÔÎÄÛÀÉÃÃÇÏÉÇÓÅÛøÀ
`ÆÃÎÏÅÔÄÆÆÉöÀÆÇÀøÇÓÀÅÂÇÓÛöÀùÉÀÄÔÔÉöÄÎÆÉÛøÀöÉÅÆÃÇøÉöËÀ
`)
`
`(
`
`

`

`0 Q
`
`This email and any attachments thereto may contain private, confidential, and privileged material for the sole
`+-.02?3-<0358035:03773>+?257.07+2,2760?3:0>6573-50C,-4372/0>659-8257-3</03580C,-4-<2P280?372,-3<096,07+20.6<20
`use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by
`K.206907+20-57258280,2>-C-257@00 5:0,24-2B/0>6C:-5P/06,08-.7,-MK7-6506907+-.02?3-<0D6,035:03773>+?257.07+2,276J0M:0
`others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and
`67+2,.0-.0.7,->7<:0C,6+-M-728@0090:6K03,2056707+20-57258280,2>-C-257/0C<23.20>6573>707+20.2582,0-??28-372<:03580
`permanently delete the original and any copies of this email and any attachments thereto.
`C2,?35257<:082<27207+206,-P-53<0358035:0>6C-2.06907+-.02?3-<0358035:03773>+?257.07+2,276@0
`
`¡
`
`